Idiopathic Pulmonary Fibrosis (IPF) Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) - Estimates DelveInsight | FibroGen, Bellerophon, MediciNova, Novartis, Avalyn, Bristol-Myers Squibb, Galecto Biotech, CSL Behring

As per DelveInsight, the Idiopathic Pulmonary Fibrosis Market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies assisted by an increase in the diagnosed prevalent population of Idiopathic Pulmonary Fibrosis in the 7MM.

DelveInsight's "Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Idiopathic Pulmonary Fibrosis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Idiopathic Pulmonary Fibrosis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Idiopathic Pulmonary Fibrosis (IPF): An Overview
The term "idiopathic" refers to a condition that has no known cause. Scarring produces stiffness in the lungs, making breathing harder. The most prevalent type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). It is a lung illness that produces scarring (fibrosis).

Scarring produces stiffness in the lungs, making breathing harder. Idiopathic Pulmonary Fibrosis causes irreversible and progressive lung damage, which means it becomes worse over time. Certain drugs can help to slow it down in some circumstances. Lung transplantation is occasionally indicated for persons with Idiopathic Pulmonary Fibrosis.

The signs and symptoms of Idiopathic Pulmonary Fibrosis appear gradually and may not show up until the disease has caused significant lung damage. These are likely to deteriorate over time if they occur. Shortness of breath (dyspnea), and dry coughing which eventually leads to chronic coughing in about 85% of the people with Idiopathic Pulmonary Fibrosis are some of the most common signs and symptoms of Idiopathic Pulmonary Fibrosis.

There are several diagnostic tools available, and the consensus guidelines have been well-defined to identify Idiopathic Pulmonary Fibrosis. Pulmonary function tests are performed to assess for restrictive lung disease, which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When Idiopathic Pulmonary Fibrosis is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like x-rays are done, but when they are not detailed enough to confirm Idiopathic Pulmonary Fibrosis. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.

Idiopathic Pulmonary Fibrosis (IPF) Market Key Facts
The Idiopathic Pulmonary Fibrosis market size in seven major markets was USD 3,167 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 6.6% for the study period (2019-2032).
The United States accounts for the largest Idiopathic Pulmonary Fibrosis market size, with approximately USD 2,321 million in 2021.
The total Idiopathic Pulmonary Fibrosis Market Size in the EU-5 was USD 693 million in 2021, which is anticipated to grow at a CAGR of 7.8%.
Japan accounted for USD 153 million market share in 2021 i.e. 5% of the total Idiopathic Pulmonary Fibrosis Market Size in the 7MM.
The total Idiopathic Pulmonary Fibrosis diagnosed prevalent cases in the 7MM was 194,878 cases in 2021.
The highest Idiopathic Pulmonary Fibrosis diagnosed prevalent cases was accounted for by the US in 2021, with 94,700+ cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.
Among the European countries, Germany had the highest diagnosed prevalent population of Idiopathic Pulmonary Fibrosis with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.

Get a Detailed Overview of the Evolving Idiopathic Pulmonary Fibrosis Market Trends @
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Idiopathic Pulmonary Fibrosis (IPF) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Idiopathic Pulmonary Fibrosis therapies in the market. It also provides a detailed assessment of the Idiopathic Pulmonary Fibrosis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Idiopathic Pulmonary Fibrosis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Idiopathic Pulmonary Fibrosis Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Idiopathic Pulmonary Fibrosis (IPF) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Idiopathic Pulmonary Fibrosis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Idiopathic Pulmonary Fibrosis Epidemiology Segmented as -
Diagnosed prevalent cases of idiopathic pulmonary fibrosis
Gender-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis
Age-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis
Severity-specific diagnosed prevalent cases of idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis (IPF) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to be launched during the study period. The analysis covers the market share by Idiopathic Pulmonary Fibrosis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Idiopathic Pulmonary Fibrosis Market @
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Assessment
The therapeutic approach of Idiopathic Pulmonary Fibrosis involves both non-pharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong survival. There are two antifibrotic agents, ESBRIET (Roche) and OFEV (Boehringer Ingelheim) approved for use in Idiopathic Pulmonary Fibrosis. Both drugs are known to slow the disease progression but do not significantly impact mortality.

To further improve the treatment, scenario, several major pharma and biotech companies are actively engaged in the development of therapeutic interventions for Idiopathic Pulmonary Fibrosis (IPF). Among these, FibroGen stands out as a notable player with its Idiopathic Pulmonary Fibrosis drug candidates advancing to the most advanced stage, namely phase III of clinical trials.

Some of the emerging upcoming Idiopathic Pulmonary Fibrosis therapies such as Pamrevlumab, PRM-151 (pentraxin-2, RG6354), Tyvaso (treprostinil), BI 1015550, and others have the potential to create a significant positive shift in the Idiopathic Pulmonary Fibrosis market size.

Leading Companies in the Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Market Include
Some of the key companies in the Idiopathic Pulmonary Fibrosis Market include FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharmaco, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, BridgeBiotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, and Ocean Biomedical.

Emerging and Marketed Idiopathic Pulmonary Fibrosis (IPF) Therapies Covered in the Report Include
DUB program: USP30 Inhibitor Mission Therapeutics
LTI-03: Lung Therapeutics
TD-1058: Theravance Biopharma
PLN-74809: Pliant Therapeutics
GB0139: Galecto Biotech
Pamrevlumab: FibroGen
PRM-151: Roche
C21: Vicore Pharma
Pamrevlumab: FibroGen
Tipelukast: MediciNova
HZN-825: Horizon Pharmaceuticals
Brilaroxazine: Reviva Pharmaceuticals
Pamrevlumab: FibroGen
Tyvaso (inhaled treprostinil): United Therapeutics
PRM-151 (RG6354): Hoffmann-La Roche Ltd
And Many Others

Learn More About the Emerging Therapies and key Companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market @
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis
4. Idiopathic Pulmonary Fibrosis Market Overview at a Glance
5. Idiopathic Pulmonary Fibrosis Background and Overview
6. Idiopathic Pulmonary Fibrosis Patient Journey
7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population
8. Idiopathic Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Idiopathic Pulmonary Fibrosis Unmet Needs
10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment
11. Idiopathic Pulmonary Fibrosis Marketed Products
12. Idiopathic Pulmonary Fibrosis Emerging Therapies
13. Idiopathic Pulmonary Fibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Idiopathic Pulmonary Fibrosis Market Outlook (7 major markets)
16. Idiopathic Pulmonary Fibrosis Access and Reimbursement Overview
17. KOL Views on the Idiopathic Pulmonary Fibrosis Market.
18. Idiopathic Pulmonary Fibrosis Market Drivers
19. Idiopathic Pulmonary Fibrosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.